Avidity Biosciences develops targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates platform. The company is focused on addressing unmet patient needs across various therapeutic areas.

Avidity Biosciences

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

COM:AVIDITYBIOSCIENCES

Avidity Biosciences

Last Close

44.00

25/09 14:39

Market Cap

5.59B

Beta: -

Volume Today

163.85K

Avg: -

Filings Not Available